• Citer

Risk prediction for patients with early HR+, HER2-, node-positive breast cancer: How to best integrate clinicopathologic and genomic tests?

par Sotiriou, Christos
Référence ESMO Breast Cancer Congress (ESMO Colloquium supported by Lilly) (May 3, 2022: Berlin, Germany)
Publication Non publié, 2022-05-03

Communication à un colloque

• Détails

Titre:	Risk prediction for patients with early HR+, HER2-, node-positive breast cancer: How to best integrate clinicopathologic and genomic tests?
Auteur:	Sotiriou, Christos
Informations sur la publication:	ESMO Breast Cancer Congress (ESMO Colloquium supported by Lilly) (May 3, 2022: Berlin, Germany)
Statut de publication:	Non publié, 2022-05-03
Sujet CREF:	Cancérologie
Langue:	Anglais